This is an excellent infographic ,a summary of the beta-lactamase inhibitors reviewed in the new @SIDPharm#Breakpoints episode "Beta-lactamase inhibitors: Scientifically elegant, just complex."
Link to podcast: EnJoy! https://t.co/b3bkwBRDkm
#idxposts#bookmark
Tazobactam dosing: one companion, different partners. 🤝
🆕✨🟢 Population PK analysis in critically ill patients:
⚡️ ARC → ↑ tazobactam clearance
📉 Standard dosing → risk of underexposure
💥 Surprising: underexposure was more pronounced when tazobactam was co-administered with ceftolozane than with piperacillin under standard dosing
💉 Higher-dose continuous infusion → improved target attainment #IDXposts
https://t.co/HTwtWu05x8
🆕💥🟢 The Clash of the Titans
Ceftolozane/tazobactam 🆚 ceftazidime/avibactam: AAC
📊 Large national VHA retrospective cohort
👥 260 patients from 66 U.S. hospitals
🦠 Hospitalized adults with multidrug-resistant Pseudomonas aeruginosa pneumonia
🔍 Head-to-head: no significant difference in clinical outcomes.
⚖️ No clear winner.
🎯 Comparable outcomes — let the evidence guide the choice.
#IDXposts
https://t.co/9ApwDHWL2P
🔥🔥Back online🔥🔥
IDSA/ESCMID 2026 Guidelines on Staphylococcus aureus Bacteremia: Risk Stratification, Diagnostic Evaluation, and Management of Adults and Children Part-1
#IDXposts
https://t.co/X1kOKsrVfg
💥IDSA AMR Guidance 2026 Now published in CID💥
Infectious Diseases Society of America 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
🔺ESBL , AmpC Enterobacterales
🔺CRE
🔺DTR P. aeruginosa
🔺CRAB
🔺Stenotrophomonas maltophilia #IDXposts
https://t.co/eddrrRIkMI